Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
August 24, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma strengthens commercialization leadership team

LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
August 19, 2022 02:46 ET | Source: Verona Pharma plc

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
August 15, 2022 16:05 ET | Source: Verona Pharma plc

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
August 10, 2022 20:22 ET | Source: Verona Pharma plc

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
August 09, 2022 16:16 ET | Source: Verona Pharma plc

Verona Pharma plc Announces Proposed Underwritten Public Offering

LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
August 09, 2022 03:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 ...
August 09, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24 weeks Well tolerated with safety results similar to placebo Conference call...
August 08, 2022 16:30 ET | Source: Verona Pharma plc

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD

LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
July 29, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...